Bond.az White LogoBond.az Black Logo

Goldman Sachs Downgrades Eiffage Stock

Goldman Sachs downgrades Eiffage to Neutral, cuts price target to €148. Cites Europe and France economic challenges.

Alexander Gonzalez
ByAlexander Gonzalez- Senior Editor
|
0

Bond.az - Goldman Sachs downgraded Eiffage SA (FGR:FP) (OTC:EFGSY) to Neutral from Buy and lowered its price target to EUR148.00 from EUR157.00. The stock has declined 13.7% over the past week, though analysis suggests the shares remain undervalued.

The firm reduced its EBIT and earnings per share estimates by 4% and 6% on average for 2026-29 to reflect a more challenging economic backdrop in Europe and France. The revised estimates incorporate lower toll road traffic and construction projections for 2026 and beyond.

Goldman Sachs said the risk-reward profile appears more balanced relative to its broader coverage. The firm's 2026 and 2027 EBIT estimates stand 2% and 5% below Bloomberg consensus.

Weaker road traffic trends, new lows on the French construction PMI, and an elevated corporate tax rate are likely to limit positive momentum. Political risk is unlikely to compress ahead of presidential elections in France in April 2027 and upcoming 2027 budget debates.

Eiffage's valuation has been highly sensitive to French sovereign spreads. The firm maintains a structurally positive medium-term view on the company's electrical engineering business. The company trades at a P/E ratio of 11.92, gross profit margin of 84%, and offers a dividend yield of 3.05% after raising dividends for six consecutive years.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
730

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...